04:54 AM EDT, 10/06/2025 (MT Newswires) -- Oculis Holding ( OCS ) said Monday it is advancing its Privosegtor product candidate to a registrational program for neuro-ophthalmology indications following a "positive meeting" with the US Food and Drug Administration.

The company plans to start the program this year, with three trials to support the registration process. The first trial is targeted to start in Q4 and the second in H1 2026, both of which will evaluate Privosegtor as a therapy for acute optic neuritis.

Oculis said it expects to start the third trial in mid-2026, to evaluate Privosegtor after the acute onset of non-arteritic anterior ischemic optic neuropathy.